Evidence map›Paper›PMID 24145437›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2013

BC-box protein domain-related mechanism for VHL protein degradation.

Maria Elena Pozzebon, Archana Varadaraj, Domenico Mattoscio, Ellis G Jaffray, Claudia Miccolo, Viviana Galimberti, Massimo Tommasino, Ronald T Hay, Susanna Chiocca

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 37 citations in OpenAlex.

  1. Von Hippel-Lindau/Hypoxia Inducible Factor Axis in Glioblastoma.International journal of molecular sciences · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. HPV-mediated regulation of SMAD4 modulates the DNA damage response in head and neck cancer.Journal of experimental & clinical cancer research : CR · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. CRL4The EMBO journal · 2018
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 4 countries.

Maria Elena PozzebonDepartment of Experimental Oncology, European Institute of Oncology, 20139 Milan, Italy.
Archana Varadaraj
Domenico Mattoscio
Ellis G Jaffray
Claudia Miccolo
Viviana Galimberti
Massimo Tommasino
Ronald T Hay
Susanna Chiocca
European Institute of Oncology · ITUniversity of Dundee · GBCentre International de Recherche sur le Cancer · FR

Funding

Wellcome Trust 097945
6 · The paper itself

Abstract

The tumor suppressor VHL (von Hippel-Lindau) protein is a substrate receptor for Ubiquitin Cullin Ring Ligase complexes (CRLs), containing a BC-box domain that associates to the adaptor Elongin B/C. VHL targets hypoxia-inducible factor 1α to proteasome-dependent degradation. Gam1 is an adenoviral protein, which also possesses a BC-box domain that interacts with the host Elongin B/C, thereby acting as a viral substrate receptor. Gam1 associates with both Cullin2 and Cullin5 to form CRL complexes targeting the host protein SUMO enzyme SAE1 for proteasomal degradation. We show that Gam1 protein expression induces VHL protein degradation leading to hypoxia-inducible factor 1α stabilization and induction of its downstream targets. We also characterize the CRL-dependent mechanism that drives VHL protein degradation via proteasome. Interestingly, expression of Suppressor of Cytokine Signaling (SOCS) domain-containing viral proteins and cellular BC-box proteins leads to VHL protein degradation, in a SOCS domain-containing manner. Our work underscores the exquisite ability of viral domains to uncover new regulatory mechanisms by hijacking key cellular proteins.

Indexed as

ProteolysisCell Line, TumorCullin ProteinsDNA PrimersElonginGene Knockdown TechniquesHumansImmunoblottingImmunoprecipitationLuciferasesProtein Structure, TertiaryReal-Time Polymerase Chain ReactionSuppressor of Cytokine Signaling 1 ProteinSuppressor of Cytokine Signaling ProteinsTranscription FactorsUbiquitin-Protein Ligase ComplexesCELO protein, adenovirusCullin ProteinsDNA PrimersELOB protein, humanElonginLuciferasesSOCS1 protein, humanSuppressor of Cytokine Signaling 1 ProteinSuppressor of Cytokine Signaling ProteinsTranscription FactorsUbiquitin-Protein Ligase ComplexesViral ProteinsVon Hippel-Lindau Tumor Suppressor Proteinhypoxiaoncoviral proteinsubiquitylation

Identifiers

PMID24145437
PMCPMC3831490
OpenAlexW2045640538

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.